Literature DB >> 15034046

Identifiying human MHC supertypes using bioinformatic methods.

Irini A Doytchinova1, Pingping Guan, Darren R Flower.   

Abstract

Classification of MHC molecules into supertypes in terms of peptide-binding specificities is an important issue, with direct implications for the development of epitope-based vaccines with wide population coverage. In view of extremely high MHC polymorphism (948 class I and 633 class II HLA alleles) the experimental solution of this task is presently impossible. In this study, we describe a bioinformatics strategy for classifying MHC molecules into supertypes using information drawn solely from three-dimensional protein structure. Two chemometric techniques-hierarchical clustering and principal component analysis-were used independently on a set of 783 HLA class I molecules to identify supertypes based on structural similarities and molecular interaction fields calculated for the peptide binding site. Eight supertypes were defined: A2, A3, A24, B7, B27, B44, C1, and C4. The two techniques gave 77% consensus, i.e., 605 HLA class I alleles were classified in the same supertype by both methods. The proposed strategy allowed "supertype fingerprints" to be identified. Thus, the A2 supertype fingerprint is Tyr(9)/Phe(9), Arg(97), and His(114) or Tyr(116); the A3-Tyr(9)/Phe(9)/Ser(9), Ile(97)/Met(97) and Glu(114) or Asp(116); the A24-Ser(9) and Met(97); the B7-Asn(63) and Leu(81); the B27-Glu(63) and Leu(81); for B44-Ala(81); the C1-Ser(77); and the C4-Asn(77).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034046     DOI: 10.4049/jimmunol.172.7.4314

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  MHC class II DRB diversity in raccoons (Procyon lotor) reveals associations with raccoon rabies virus (Lyssavirus).

Authors:  Vythegi Srithayakumar; Sarrah Castillo; Rick C Rosatte; Christopher J Kyle
Journal:  Immunogenetics       Date:  2010-10-06       Impact factor: 2.846

2.  Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?

Authors:  Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  Expert Rev Vaccines       Date:  2012-01       Impact factor: 5.217

Review 3.  MHC class II epitope predictive algorithms.

Authors:  Morten Nielsen; Ole Lund; Søren Buus; Claus Lundegaard
Journal:  Immunology       Date:  2010-04-12       Impact factor: 7.397

Review 4.  Major histocompatibility complex class I binding predictions as a tool in epitope discovery.

Authors:  Claus Lundegaard; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunology       Date:  2010-05-26       Impact factor: 7.397

5.  Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires.

Authors:  John Sidney; Scott Southwood; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-07-08       Impact factor: 2.846

6.  Principal component analysis of native ensembles of biomolecular structures (PCA_NEST): insights into functional dynamics.

Authors:  Lee-Wei Yang; Eran Eyal; Ivet Bahar; Akio Kitao
Journal:  Bioinformatics       Date:  2009-01-15       Impact factor: 6.937

7.  Designing immunogenic peptides.

Authors:  Darren R Flower
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

8.  HLA-DP2 binding prediction by molecular dynamics simulations.

Authors:  Irini Doytchinova; Peicho Petkov; Ivan Dimitrov; Mariyana Atanasova; Darren R Flower
Journal:  Protein Sci       Date:  2011-09-27       Impact factor: 6.725

Review 9.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

10.  Polymorphism, haplotype composition, and selection in the Mhc-DRB of wild baboons.

Authors:  Elise Huchard; Mylene Weill; Guy Cowlishaw; Michel Raymond; Leslie A Knapp
Journal:  Immunogenetics       Date:  2008-08-05       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.